Findings of a large, global clinical trial reported at the 2022 San Antonio Breast Cancer Symposium on Dec. 6 and led by senior author Kevin Kalinsky, MD, MS, of Winship Cancer Institute of Emory University found that non-Hispanic Black (Black) women with hormone receptor (HR) positive/HER2 negative breast cancer, with 1-3 involved lymph nodes and recurrence scores below 25, have worse outcomes than non-Hispanic white (white) women with similar diagnosis.
2023 Calendar of Hope Cover

Our 2023 Calendar

This month Sisters’ Journey thanks our February Sponsor of the Month “Michael Imevbore of Connecticut Pulmonary Specialist” As a sponsor, his contribution has been vital in helping Sisters’ Journey to continue our important work in the community. We thank you Dr. Michael Imevbore, we cannot succeed without the generosity of supporters like you. 

For more information about Connecticut Pulmonary Specialist go to


Stay in the Know…

We’re so excited to be a part of Fairfield County’s Giving Day! You can support our campaign by visiting and donating on February 23.


“Mapping Your Cancer Journey”  Click here for you free Guide


Events Calendar

There are no upcoming events available at this time. Visit us again soon!

Cheryl Speller

Survivor of the Month

Cheryl Speller

“Scared, but not defeated!”...


  • Who we are

    Sisters’ Journey is a caring and powerful support group for breast cancer survivors, their family, and their friends.

  • Our support group

    The support group meets the 3rd Tuesday of each month at
    St.Lukes’ Parish Hall, 111 Whalley Ave, New Haven, CT 06511

  • Donate

    Sisters’ Journey, a 501(c)3 non-profit organization, seeks to aid and support women diagnosed with and who have survived breast cancer. Help us continue on our mission by making a charitable contribution.

Subscribe to our e-mail list

First name is required.
Last name is required.
E-mail address is required.
Please enter a valid e-mail address.
Thank you for your interest in Sisters' Journey. You have been subscribed successfully.
We could not subscribe you to our email list.